PegBio Co., Ltd. (02565.HK) Latest Company News

Sep 2, 2026, 09:27 UTC
Paige Biopharmaceuticals (02565) signed a material transfer agreement with SN BioScience to apply SN BioScience's SNA long-acting drug delivery platform to three of Paige's metabolic disease peptide candidates including APGP6 for joint research.
Source:
- aastocks.com
Aug 25, 2026, 11:59 UTC
PegBio Co., Ltd. received the first commercialization cooperation payment of about HK$61 million from Tenrui Pharmaceutical under an agreement for the commercialization of Paidakang in mainland China.
Source:
- nbd.com.cn
Aug 25, 2026, 08:46 UTC
Paigel Biopharmaceuticals-B (02565.HK) reported an interim loss of RMB 216 million for the six months ended June 2026, widening from a loss of RMB 93.672 million in the same period last year, with no revenue recorded and no dividend declared.
Source:
- aastocks.com
- nbd.com.cn
Aug 13, 2026, 20:05 UTC
Rani Therapeutics entered into a research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill platform.
Source:
- globenewswire.com
Aug 13, 2026, 13:00 UTC
Lexaria Bioscience Corp. entered into a Material Transfer Agreement with PegBio Co., Ltd to investigate Lexaria's DehydraTECH technology with a PegBio molecule under development for the GLP-1 industry.
Source:
Jul 22, 2026, 10:08 UTC
Paige Biotech's new drug Paidakang has received its first commercial prescriptions across multiple medical institutions and online channels in China.
Source:
- aastocks.com
Jul 17, 2026, 11:51 UTC
Alibaba Health announced a strategic partnership with Shanghai Tengrui Pharmaceutical and Pangen Biomedical, with the core product Paidakang (Vipenatide Injection) to be launched on Alibaba Health's platform.
Source:
- finance.sina.cn

02565.HK

Paige Biopharmaceuticals (02565) signed a material transfer agreement with SN BioScience to apply SN BioScience's SNA long-acting drug delivery platform to three of Paige's metabolic disease peptide candidates including APGP6 for joint research.

PegBio Co., Ltd. received the first commercialization cooperation payment of about HK$61 million from Tenrui Pharmaceutical under an agreement for the commercialization of Paidakang in mainland China.

Paigel Biopharmaceuticals-B (02565.HK) reported an interim loss of RMB 216 million for the six months ended June 2026, widening from a loss of RMB 93.672 million in the same period last year, with no revenue recorded and no dividend declared.

Rani Therapeutics entered into a research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill platform.

Lexaria Bioscience Corp. entered into a Material Transfer Agreement with PegBio Co., Ltd to investigate Lexaria's DehydraTECH technology with a PegBio molecule under development for the GLP-1 industry.

Paige Biotech's new drug Paidakang has received its first commercial prescriptions across multiple medical institutions and online channels in China.

Alibaba Health announced a strategic partnership with Shanghai Tengrui Pharmaceutical and Pangen Biomedical, with the core product Paidakang (Vipenatide Injection) to be launched on Alibaba Health's platform.